The inspiration for this column comes not from the epic 1999 film The Matrix, as the title may suggest, but from an episode of Sean Carroll’s Mindscape podcast that I listened to over the summer. The ...

PARIS — Results from the REMAIN long-term follow-up study on MCO-010, an optogenetic therapy for retinitis pigmentosa, showed durable efficacy over 3 years.